A041703 / CLEU19006 / O'Dwyer, Kristen
Basic Study Information
Purpose:Location: University of Rochester
This phase II trial studies how well inotuzumab ozogamicin and blinatumomab work in
treating patients with CD22-positive B-lineage acute lymphoblastic leukemia that is
newly diagnosed, has come back, or does not respond to treatment. Immunotherapy with
monoclonal antibodies, such as inotuzumab ozogamicin and blinatumomab, may help the
body's immune system attack the cancer, and may interfere with the ability of tumor
cells to grow and spread.
Lead Researcher (Principal Investigator)
Study Contact InformationStudy Coordinator: Jessica Mackowiak
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search